Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GSK to Reduce Drug Patents in Poor Countries

By Drug Discovery Trends Editor | March 31, 2016

Kirsty Wigglesworth/APIn an attempt to broaden global access to expensive medications, GlaxoSmithKline (GSK) announced Thursday it will adopt a graduated approach to patenting its drugs, depending on the wealth of countries.

This approach will make it easier for companies in the world’s poorest countries to manufacture generics of its medications, the Britain-based company said.

The pharmaceuticals industry has in the past used tiered pricing in poorer countries, but this is the first time a company has decided to waive its patent rights in particular nations.

The approach is expected to only have minimal impact on GSK’s group earnings, reported Reuters.

GSK has compiled a list of about 50 countries with a combined population of nearly 1 billon people, where it will not file for patents. In lower middle-income countries, GSK said it will continue to seek patents but will grant license deals that allow generic versions of its drugs to sell for 10 years (in exchange for a “small royalty”). In high- and upper middle-income countries — including China, Brazil and India — the company will continue to seek full patent protection.

GSK CEO Sir Andrew Witty, who will step down next year, said he anticipates Africa will benefit the most from this plan.

“The changes we are setting out aim to make it as clear and simple as possible for generic manufacturers to make and supply versions of GSK medicines,” said Witty.

Also, GSK will place its next-generation cancer drugs into a Medicines Patent Pool (MPP) and allow access to competitors. MPP has helped accelerate access to treatments for HIV and hepatitis C to developing countries.

Last year, GSK sold its established cancer drugs to Novartis in exchange for the company’s consumer healthcare and vaccines businesses.

Read more: How Cancer Survivors are Affected by Financial Burdens

Specialty drug costs, particularly cancer treatments, have risen dramatically. In the U.S. the cost of all cancer care totaled $124.5 billion in 2010, according to a 2011 study in the Journal of the National Cancer Institute. That total cost is projected to rise to $157.7 billion by 2020.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE